TG Therapeutics (TGTX) Nyanmɛn Kpɛn
AI bɛ́nɛ́nɛ́: TGTX
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved diseases. The company is developing two treatments for hematologic malignancies, specifically relapsed and refractory non-Hodgkin lymphoma.
